Regeneron Pharmaceuticals' Enterprise Value fell 51.78% to $51.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $26.3 billion, marking a year-over-year decrease of 64.87%. This contributed to the annual value of $69.3 billion for FY2024, which is 18.36% down from last year.
According to the latest figures from Q3 2025, Regeneron Pharmaceuticals' Enterprise Value is $51.1 billion, which was up 3.94% from $49.2 billion recorded in Q2 2025.
Regeneron Pharmaceuticals' Enterprise Value's 5-year high stood at $106.1 billion during Q3 2024, with a 5-year trough of $47.2 billion in Q1 2021.
Its 3-year average for Enterprise Value is $77.5 billion, with a median of $79.4 billion in 2023.
Its Enterprise Value has fluctuated over the past 5 years, first surged by 51.64% in 2024, then slumped by 53.57% in 2025.
Over the past 5 years, Regeneron Pharmaceuticals' Enterprise Value (Quarterly) stood at $62.2 billion in 2021, then climbed by 13.84% to $70.8 billion in 2022, then increased by 19.78% to $84.8 billion in 2023, then declined by 18.36% to $69.3 billion in 2024, then plummeted by 51.78% to $51.1 billion in 2025.
Its Enterprise Value was $51.1 billion in Q3 2025, compared to $49.2 billion in Q2 2025 and $61.0 billion in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value